Logo image of AMRX

AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis

NASDAQ:AMRX - Nasdaq - US03168L1052 - Common Stock - Currency: USD

8.28  -0.11 (-1.31%)

Fundamental Rating

4

AMRX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While AMRX is still in line with the averages on profitability rating, there are concerns on its financial health. AMRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year AMRX was profitable.
In multiple years AMRX reported negative net income over the last 5 years.
AMRX had a positive operating cash flow in each of the past 5 years.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

AMRX has a Return On Assets of -0.39%. This is amongst the best in the industry. AMRX outperforms 81.03% of its industry peers.
AMRX has a Return On Invested Capital of 11.15%. This is amongst the best in the industry. AMRX outperforms 89.23% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMRX is significantly below the industry average of 14.87%.
The 3 year average ROIC (7.98%) for AMRX is below the current ROIC(11.15%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -0.39%
ROE N/A
ROIC 11.15%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300 -400

1.3 Margins

AMRX has a better Operating Margin (12.87%) than 84.10% of its industry peers.
In the last couple of years the Operating Margin of AMRX has grown nicely.
AMRX has a Gross Margin of 36.69%. This is comparable to the rest of the industry: AMRX outperforms 59.49% of its industry peers.
AMRX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 12.87%
PM (TTM) N/A
GM 36.69%
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

AMRX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, AMRX has less shares outstanding
AMRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, AMRX has an improved debt to assets ratio.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

AMRX has an Altman-Z score of 1.56. This is a bad value and indicates that AMRX is not financially healthy and even has some risk of bankruptcy.
AMRX has a better Altman-Z score (1.56) than 62.56% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 1.56
ROIC/WACC1.01
WACC11.03%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

AMRX has a Current Ratio of 1.40. This is a normal value and indicates that AMRX is financially healthy and should not expect problems in meeting its short term obligations.
AMRX has a Current ratio of 1.40. This is in the lower half of the industry: AMRX underperforms 70.77% of its industry peers.
A Quick Ratio of 0.84 indicates that AMRX may have some problems paying its short term obligations.
With a Quick ratio value of 0.84, AMRX is not doing good in the industry: 81.54% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 0.84
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

AMRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.52%.
AMRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.63% yearly.
Looking at the last year, AMRX shows a quite strong growth in Revenue. The Revenue has grown by 16.73% in the last year.
AMRX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.43% yearly.
EPS 1Y (TTM)-1.52%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%50%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%5.5%

3.2 Future

Based on estimates for the next years, AMRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.95% on average per year.
Based on estimates for the next years, AMRX will show a small growth in Revenue. The Revenue will grow by 0.60% on average per year.
EPS Next Y24.28%
EPS Next 2Y19.84%
EPS Next 3Y21.11%
EPS Next 5Y11.95%
Revenue Next Year8.6%
Revenue Next 2Y7.96%
Revenue Next 3Y7.47%
Revenue Next 5Y0.6%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 12.74, the valuation of AMRX can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 88.72% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.47, AMRX is valued rather cheaply.
A Price/Forward Earnings ratio of 9.94 indicates a reasonable valuation of AMRX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 83.59% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.91, AMRX is valued rather cheaply.
Industry RankSector Rank
PE 12.74
Fwd PE 9.94
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

88.72% of the companies in the same industry are more expensive than AMRX, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.02
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of AMRX may justify a higher PE ratio.
A more expensive valuation may be justified as AMRX's earnings are expected to grow with 21.11% in the coming years.
PEG (NY)0.52
PEG (5Y)1.2
EPS Next 2Y19.84%
EPS Next 3Y21.11%

More info and screens

0

5. Dividend

5.1 Amount

AMRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (7/11/2025, 3:43:06 PM)

8.28

-0.11 (-1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-02 2025-05-02/bmo
Earnings (Next)08-08 2025-08-08/bmo
Inst Owners40.32%
Inst Owner Change0%
Ins Owners46.63%
Ins Owner Change1.97%
Market Cap2.60B
Analysts82
Price Target11.9 (43.72%)
Short Float %3.46%
Short Ratio2.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.76%
Min EPS beat(2)-22.85%
Max EPS beat(2)40.37%
EPS beat(4)3
Avg EPS beat(4)11.74%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)33.87%
EPS beat(12)9
Avg EPS beat(12)22.89%
EPS beat(16)11
Avg EPS beat(16)18.04%
Revenue beat(2)1
Avg Revenue beat(2)-1.74%
Min Revenue beat(2)-4.71%
Max Revenue beat(2)1.22%
Revenue beat(4)2
Avg Revenue beat(4)-0.03%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)4.54%
Revenue beat(8)5
Avg Revenue beat(8)0.71%
Revenue beat(12)8
Avg Revenue beat(12)0.66%
Revenue beat(16)9
Avg Revenue beat(16)-0.12%
PT rev (1m)1.45%
PT rev (3m)1.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.56%
EPS NY rev (1m)2.42%
EPS NY rev (3m)3.92%
Revenue NQ rev (1m)1.23%
Revenue NQ rev (3m)-1.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.58%
Valuation
Industry RankSector Rank
PE 12.74
Fwd PE 9.94
P/S 0.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 8.02
EPS(TTM)0.65
EY7.85%
EPS(NY)0.83
Fwd EY10.06%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS9.03
BVpS-0.42
TBVpS-4.53
PEG (NY)0.52
PEG (5Y)1.2
Profitability
Industry RankSector Rank
ROA -0.39%
ROE N/A
ROCE 15.91%
ROIC 11.15%
ROICexc 11.42%
ROICexgc 23.32%
OM 12.87%
PM (TTM) N/A
GM 36.69%
FCFM N/A
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexcg growth 3Y25.12%
ROICexcg growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-ScoreN/A
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 4.16
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 0.84
Altman-Z 1.56
F-ScoreN/A
WACC11.03%
ROIC/WACC1.01
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.52%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%50%
EPS Next Y24.28%
EPS Next 2Y19.84%
EPS Next 3Y21.11%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%5.5%
Revenue Next Year8.6%
Revenue Next 2Y7.96%
Revenue Next 3Y7.47%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year10.72%
EBIT Next 3Y9.83%
EBIT Next 5Y3.87%
FCF growth 1Y-20.36%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y-14.61%
OCF growth 3Y6.86%
OCF growth 5Y180.48%